Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Drug that cuts off a tumor’s blood supply shows promising results when paired with chemotherapy


An experimental drug designed to cut off a tumor’s blood supply showed promising results in patients with advanced colorectal cancer when paired with standard chemotherapy, according to a UCLA Jonsson Cancer Center study published in the Jan. 1 issue of the Journal of Clinical Oncology.

The results of this and subsequent studies of the experimental drug Avastin could change the way oncologists treat patients with this devastating form of cancer, said Dr. Fairooz Kabbinavar, a Jonsson Cancer Center researcher and first author of the peer-reviewed journal article. The combination of Avastin and chemotherapy proved superior to chemotherapy alone in treating advanced colorectal cancer, Kabbinavar said.

"This is a first-ever randomized trial of a potent anti-angiogenic agent, comparing chemotherapy alone to chemotherapy and Avastin in patients with advanced colorectal cancer," said Kabbinavar, an associate professor of hematology/oncology at UCLA who has studied this drug in the lab and in patients for the last decade. "This study could give us a less toxic and a more effective weapon in our growing arsenal of cancer therapies."

A tumor cannot grow bigger than a pinhead unless it establishes an independent blood supply through a process called angiogenesis to provide itself with oxygen and nutrients. Researchers theorize that by stopping or cutting off the new blood supply, they can starve and, they hope, kill the cancer.

In this study by UCLA’s Jonsson Cancer Center researchers and scientists at four other sites nationwide, the angiogenesis inhibitor Avastin was given with the chemotherapy drugs fluorouracil (5-FU) and leucovorin in a two-pronged attack. Researchers hoped that Avastin -- a monoclonal antibody that targets the Vascular Endothelial Growth Factor, a protein that promotes growth of blood vessels -- would help the chemotherapy work more effectively, and vice-versa, providing a synergistic effect.

Results from laboratory and early-phase studies confirm that the drugs help each other to work better, Kabbinavar said.

Patients in the Phase II study detailed in the journal article who received Avastin with chemotherapy had better response rates and median survival times than did patients who were given chemotherapy alone. In addition, those who received the combination also had a longer time before their cancer progressed and had lower levels of a colon cancer marker in their blood than did patients who received chemotherapy alone, Kabbinavar said.

"The patients who got Avastin and chemotherapy did better in all the parameters we use to measure efficacy," Kabbinavar said. "This is a promising study that provided strong enough results to move on to a large Phase III study involving 1,000 patients."

The Phase III study, also conducted at UCLA’s Jonsson Cancer Center and other sites nationwide, was recently completed. Results are expected sometime next year and should provide researchers with a more definitive answer, Kabbinavar said.

"Our hope and our expectation is that the data will hold true in the larger study as well," Kabbinavar said. "This drug combination may prove to be an important new option for patients with newly diagnosed metastatic colorectal cancer."

Avastin and other angiogenesis inhibitors attack cancer differently than do conventional therapies. Chemotherapy works like a non-specific bomb inside the body, attacking all fast-growing cells and often resulting in debilitating side effects such as nausea, hair loss and a dangerous drop in white and red blood cell counts. Angiogenesis inhibitors fight cancer by preventing or cutting off the blood supply that tumors must have to thrive and spread.

In this Phase II study, 104 patients with untreated, advanced colorectal cancer were given Avastin and chemotherapy or chemotherapy alone. Median survival was increased from about 13 months in patients who received chemotherapy alone to about 21.5 months in patients who were given Avastin and chemotherapy.

Median time to progression, or the time until the cancer grows again after treatment, was increased from 5.2 months in the chemotherapy only group to 9 months in the group receiving Avastin and chemotherapy.

Response rates also were better, with 40 percent of the group getting the combination therapy showing a significant response to the drug, versus 17 percent who responded to the chemotherapy alone.

And patients who received the combination therapy had a 54 percent lower risk of disease progression than did those on chemotherapy alone.

"These preliminary results suggest that Avastin, in combination with 5-FU and leucovorin, increases response rate, prolongs time to progression and prolongs survival," the article states. "These data support further evaluation of the efficacy and safety of Avastin."

Colorectal cancer will strike about 148,000 Americans next year alone, according to the American Cancer Society. More than 56,600 people will die from the disease.

Advanced colorectal cancer is incurable, Kabbinavar said. Most patients die within a year, so it’s vital to find new and better ways to treat this disease.

"It’s important for patients with advanced cancers to talk to their oncologists to see if there are any clinical trials available," he said. "They need to be proactive and seek out all options."

For more information on Jonsson Cancer Center studies, call 888-798-0719.

Kim Irwin | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Greater Range and Longer Lifetime

26.10.2016 | Power and Electrical Engineering

VDI presents International Bionic Award of the Schauenburg Foundation

26.10.2016 | Awards Funding

3-D-printed magnets

26.10.2016 | Power and Electrical Engineering

More VideoLinks >>>